Developing novel allergy vaccines targeting the most common allergies
Anergis has raised €31M across 3 funding rounds from 3 investors, most recently a Series C round in Apr 2016. Based in Epalinges, Switzerland; active in Healthtech. Data as of 6 Aug 2026.
Timing: dormant vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2016-04-01 | Series C | €4.6M | — | View deal → |
| 2014-12-01 | Series B | €12M | — | View deal → |
| 2011-03-01 | Series A | €14M | BioMed Partners,Sunstone Capital,Vinci Capital | View deal → |
